Table of Contents
| << Previous Issue | Jul 2025 (Vol: 2025, Issue: 7) | Next Issue >> |
- Section: Licensing
-
Gilead Sciences Inks US$750 M Deal with Kymera Therapeutics for Novel Oral Molecular Glue CDK2 Degraders
- Section: Mergers & Acquisitions
-
Merck Expands Respiratory Portfolio with US$10 B Acquisition of Verona Pharma
-
AbbVie Acquires Capstan Therapeutics and its CART-T Therapy CPTX2309 for US$2.1 B
- Section: Research & Development
-
Novartis Collaborates with ProFound Therapeutics to Develop Cardiovascular Therapies



RSS